苯磺酸氨氯地平片联合厄贝沙坦片治疗原发性高血压的临床疗效观察

目的探讨苯磺酸氨氯地平片联合厄贝沙坦片治疗原发性高血压的临床疗效观察。方法选取2018年10月～2019年10月我院收诊的72例原发性高血压患者进行治疗,按照接诊顺序奇偶性分为观察组和对照组,各36例。观察组选择苯磺酸氨氯地平片联合厄贝沙坦片治疗,对照组选择单纯性苯磺酸氨氯地平片进行治疗。对比两组临床疗效、血压变化情况、不良反应发生率。结果观察组的临床治疗总有效率为94.44%,高于对照组的72.22%,差异有统计学意义(P0.05);观察组的不良反应总发生率(5.56%)低于对照组(30.56%),差异有统计学意义(P0.05);治疗前两组血压变化情况比较差异无统计学意义(P0.05);治疗后,相较于对照组,观察组的血压显著降低,差异有统计学意义(P0.05)。结论针对原发性高血压患者,采用苯磺酸氨氯地平片联合厄贝沙坦片治疗,可显著改善患者的生活质量,取得更好的治疗效果,降低不良反应发生率,改善患者血压情况,加快疾病康复速度,具有临床应用价值。

Clinical efficacy observation of amlodipine besylate tablets combined with irbesartan tablets in the treatment of primary hypertension

Objective To investigate the clinical efficacy observation of amlodipine besylate tablets combined with irbesartan tablets in the treatment of primary hypertension.Methods 72 patients with primary hypertension admitted to our hospital from October 2018 to October 2019 were selected for treatment.They were divided into the observation group(n=36) and the control group(n=36) according to parity of admission order.The observation group was given amlodipine besylate tablets combined with irbesartan tablets for treatment,while the control group was given amlodipine besylate tablets for treatment.The clinical efficacy,blood pressure (BP) changes and incidence of adverse reactions were compared between the two groups.Results The total efficacy rate of clinical treatment in the observation group was 94.44%,which was higher than that in the control group(72.22%),with statistically significant difference between the two groups(P<0.05).The total incidence of adverse reactions in the observation group was 5.56%,which was lower than that in the control group (30.56%),with statistically significant difference between the two groups (P<0.05).Before treatment,the difference of BP changes between the two groups was not significant and of no statistical significance(P>0.05).After treatment,compared with the control group,the blood pressure in the observation group decreased significantly,and the difference between the two groups was significant with statistical significance(P<0.05).Conclusion For patients with primary hypertension,amlodipine besylate tablets combined with irbesartan tablets can significantly improve the life quality of patients,achieve better therapeutic effect,reduce the incidence of adverse reactions,amelioratethe blood pressure of patients,andaccelerate the recovery of the disease with great clinical application value.